(HIBL) Direxion Daily SP500 High - Overview
Etf: Leveraged, ETF, Daily, 3X, Index
Dividends
| Dividend Yield | 2.45% |
| Yield on Cost 5y | 2.64% |
| Yield CAGR 5y | 148.20% |
| Payout Consistency | 67.4% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 70.6% |
| Relative Tail Risk | 4.10% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.97 |
| Alpha | 13.95 |
| Character TTM | |
|---|---|
| Beta | 4.470 |
| Beta Downside | 4.501 |
| Drawdowns 3y | |
|---|---|
| Max DD | 69.66% |
| CAGR/Max DD | 0.41 |
Description: HIBL Direxion Daily SP500 High December 22, 2025
The Direxion Daily S&P 500® High Beta Bull 3X Shares (ticker HIBL) seeks to deliver three times the daily return of the S&P 500® High-Beta Index, using swaps, index securities and ETFs; at least 80% of its net assets (plus any leverage) are allocated to these instruments, making the fund non-diversified and highly sensitive to short-term index movements.
Key quantitative points to watch: the fund’s 30-day rolling beta to the S&P 500 typically exceeds 3.0, while its expense ratio sits around 0.95% p.a.; its leveraged nature amplifies both gains and losses, so a 2% daily move in the index can translate to roughly a 6% swing in HIBL. Macro-driven factors such as U.S. monetary policy (e.g., Fed rate changes) and equity market volatility (VIX) are primary drivers of performance, and sector concentration tends toward high-beta industries like technology and consumer discretionary, which can exacerbate drawdowns during risk-off periods.
For a deeper dive into the fund’s risk-adjusted returns and how its leverage behaves across market regimes, you might explore the analytics on ValueRay.
What is the price of HIBL shares?
Over the past week, the price has changed by +0.12%, over one month by +2.13%, over three months by +18.02% and over the past year by +64.42%.
Is HIBL a buy, sell or hold?
What are the forecasts/targets for the HIBL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 83.7 | 12.5% |
HIBL Fundamental Data Overview February 02, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 58.1m USD (58.1m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 58.1m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 58.1m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 22.39% (E(58.1m)/V(58.1m) * Re(22.39%) + (debt-free company))
Discount Rate = 22.39% (= CAPM, Blume Beta Adj.) -> capped to 17.85%
Fair Price DCF = unknown (Cash Flow 0.0)